Addex Therapeutics Ltd (ADXN)

Market Cap	8.49M +24.9%
Revenue (ttm)	217,996 -57.8%
Net Income	-8.49M
EPS	-0.08
Shares Out	147.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,302
Open	6.50
Previous Close	6.50
Day's Range	6.10 - 6.51
52-Week Range	5.41 - 12.05
Beta	1.97
Analysts	Buy
Price Target	30.00 (+383.87%)
Earnings Date	Jun 15, 2026

About ADXN

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: ADXN
• Website: https://www.addextherapeutics.com

Financial Performance

Financial numbers in CHF

Analyst Summary

According to one analyst, the rating for ADXN stock is "Buy" and the 12-month stock price target is $30.0.

Price Target

$30.0

(383.87% upside)

Analyst Consensus: Buy